A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Sara Margolin, Nils-Olof Bengtsson, Lena Carlsson, Per Edlund, Mats Hellstrom, Per Karlsson, Elisabet Lidbrink, Barbro Linderholm, Henrik Lindman, Per Malmström, Dagny Pettersson Skold, Martin Soderberg, Kenneth Villman, Jonas Bergh

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science